目的 探讨叉头框转录因子M1(FOXM1)、Polo样激酶1(PLK1)、缺氧诱导因子1α(HIF-1α)及果蝇Zeste基因增强子人类同源物2(EZH2)在乳腺癌组织中的表达及临床意义。方法 采用免疫组化法检测FoxM1、PLK1、HIF-1α及EZH2蛋白在803例乳腺浸润性导管癌和癌旁乳腺组织中的表达情况及其与乳腺癌组织临床病理特征间的关系。结果 FOXM1、PLK1、HIF-1α及EZH2在乳腺浸润性导管癌组织中的阳性表达率分别为59.78%、27.90%、43.96%和60.40%,显著高于其在癌旁乳腺组织中的表达(29.89%、0%、3.86%、20.92%),差异具有统计学意义(P<0.05)。FOXM1、PLK1、HIF-1α及EZH2的表达与乳腺癌的组织学分级、淋巴结转移及临床分期相关,与患者年龄、是否绝经及肿瘤大小无关(P>0.05)。PLK1、HIF-1α和EZH2蛋白的表达均与ER呈负相关关系,FOXM1和EZH2蛋白的表达与HER-2呈正相关关系(P<0.01)。FOXM1、PLK1、HIF-1α和EZH2蛋白的表达均具有正相关关系(P<0.01)。结论 FOXM1、PLK1、HIF-1α及EZH2可能协同参与了乳腺癌的发生、发展,并可能成为乳腺癌预后评估的重要指标。
Abstract
Objective To study the expressions and clinical significance of FOXM1, PLK1, HIF-1α and EZH2 in breast carcinoma.Methods Immunohistochemical staining was used not only to detect the expressions of FOXM1, PLK1, HIF-1α and EZH2 in 803 cases of invasive ductal breast carcinoma and para-tumor breast tissues, but also to evaluate the relationships between the expressions of FOXM1, PLK1, HIF-1α and EZH2 and the clinical pathological features of invasive ductal breast carcinoma, including the histological grade, lymph node metastasis and pTNM stage.Results Positive expression rates of FOXM1, PLK1, HIF-1α and EZH2 protein in invasive ductal breast carcinoma were 59.78%, 27.90%, 43.96% and 60.40% respectively, significantly higher than those in para-tumor breast tissues(29.89%, 0%, 3.86% and 20.92% respectively). There was a significant correlation between the expressions of FOXM1, PLK1, HIF-1α and EZH2 and the histopathological grade, lymph node metastasis and pTNM stage (P<0.05), but the expressions of FOXM1, PLK1, HIF-1α and EZH2 were not correlated with the patients’ age, menopause or tumor size. There was a significantly negative relationship between the expressions of PLK1, HIF-1α, EZH2 and ER. There was a significantly positive relationship between the expressions of Fox M1, EZH2 and HER-2 (P<0.01). The expressions of FOXM1, PLK1, HIF-1α and EZH2 in breast invasive ductal carcinoma were positively correlated(P<0.01).Conclusions The overexpressions of FOXM1, PLK1, HIF-1α and EZH2 may be involved in breast carcinogenesis and progression synergistically, and they might play an important role in the prognosis evaluation of breast carcinoma.
关键词
乳腺肿瘤 /
叉头框转录因子M1 /
Polo样激酶1 /
缺氧诱导因子1α /
果蝇Zeste基因增强子人类同源物2
Key words
breast neoplasm /
FOMX1 /
PLK1 /
HIF-1α /
EZH2
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 刘怡茜, 郭人花, 刘连科, 等. 叉头框转录因子M1在非小细胞癌中的表达及其与患者临床病理特征和生存的关系[J].中华肿瘤杂志, 2011, 33 (6): 426-430.
[2] King S I, Purdie C A, Bray S E, et al. Immunohistochemical detection of Polo-like kinase-1 (PLK1) in primary breast cancer is associated with TP53 mutation and poor clinical outcome [J]. Breast Cancer Res, 2012, 14(2): R40.
[3] Zhong H, De Marzo A M, Laughner E, et al. Overexpression of hypoxia-inducible factor- 1 alpha in common hum an cancers and their metastases [J]. Cancer Res, 1999, 59(22): 5830-5835.
[4] 汪小霞, 孟 刚, 李 丽, 等. 乳腺癌中EZH2和p53蛋白表达及其临床意义[J]. 临床与实验病理学杂志, 2015, 31(3): 273-276.
[5] Halasi M, Gartel A L. FOX(M1) news—it is cancer [J]. Mol Cancer Ther, 2013, 12(3): 245-254.
[6] Park H J, Gusarova G, Wang Z, et al. Deregulation of FoxM1b leads to tumour metastasis [J]. EMBO Mol Med, 2011, 3(1): 21-34.
[7] Millour J, Constantinidou D, Stavropoulou A V, et al. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance [J]. Oncogene, 2010, 29(20): 2983-2995.
[8] Francis R E, Myatt S S, Krol J, et al. FoxM1 is a downstream target and marker of HER2 over expression in breast cancer [J]. Int J Oncol, 2009, 35(1): 57-68.
[9] Wang G, Chen Q, Zhang X, et al. PCM1 recruits PLK1 to the pericentriolar matrix to promote primary cilia disassembly before mitotic entry [J]. J Cell Sci, 2013, 126(Pt6): 1355-1365.
[10] Song B, Liu X S, Rice S J, et al. PLK1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer [J]. Mol Cancer Ther, 2013, 12(1): 58-68.
[11] Zhang G, Zhang Z, Liu Z. Polo-like kinase 1 is overexpressed in renal cancer and participates in the proliferation and invasion of renal cancer cells [J]. Tumour Biol, 2013, 34(3): 1887-1894.
[12] Maire V, Némati F, Richardson M, et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer [J]. Cancer Res, 2013, 73(2): 813-823.
[13] Masoud G N, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy [J]. Acta Pharm Sin B, 2015, 5(5):378-389.
[14] Cai F F, Xu C, Pan X, et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer [J]. Oncotarget, 2016, 7(47): 77793-77806.
[15] 车爱文, 陈淑苹, 康凯夫. EZH2和FHIT在肝癌中的表达及其临床意义[J]. 肿瘤学杂志, 2013, 19(7): 514-517.
[16] Kim K H, Kim L, Choi S J, et al. The clinicopathological significance of epithelial mesenchymal transition associated protein expression in head and neck squamous cell carcinoma [J]. Korean J Pathol, 2014, 48(4): 263-269.
[17] Ernst T, Chase A J, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders [J]. Nat Genet, 2010, 42(8): 722-726.
[18] Kleer C G, Cao Q, Varambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells [J]. Proc Natl Acad Sci U S A, 2003, 100(20): 11606-11611.
[19] Knudsen E S, Dervishaj O, Kleer C G, et al. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer [J]. Cell Cycle, 2013, 12(13): 2042-2050.
[20] Myatt S S, Kongsema M, Man C W, et al. SUMOylation inhibits FOXM1 activity and delays mitotic transition [J]. Oncogene, 2014, 33(34): 4316-4329.
[21] Fu Z, Malureanu L, Huang J, et al. Plk1-dependent phosphorylation of FOXM1 regulates a transcriptional programme required for mitotic progression [J]. Nat Cell Biol, 2008, 10(9): 1076-1082.
[22] Mahara S, Lee P L, Feng M, et al. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer [J]. Proc Natl Acad Sci U S A, 2016, 113(26): E3735-E3744.
[23] Cao P, Deng Z, Wan M, et al. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-11alpha/HIF-1beta [J]. Mol Cancer, 2010, 9: 108.
[24] Riquelme E, Suraokar M, Behrens C, et al. VEGF/VEGFR-2 upregulatesEZH2 expression in lung adenocarcinoma cells and EZH2 depletionenhances the response to platinum-based and VEGFR-2-targeted therapy [J]. Clin Cancer Res, 2014, 20(14): 3849-3861.
[25] Geng J, Li X, Zhou Z, et al. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer [J]. Cancer Lett, 2015, 359(2): 275-287.
PDF(2227 KB)
